Table 2.
Univariable and multivariable analyses for predictive factors of OS in the training cohort of patients with breast cancer patients with ipsilateral supraclavicular lymph node metastasis.
| Univariable analysis | Multivariable analysis | |||||
| Variables | HR | 95% CI | P | HR | 95% CI | P |
| Age (years): >40 vs. ≤40 | 0.579 | 0.307–1.091 | 0.0910 | |||
| Family history of cancer: yes vs. no | 1.755 | 0.822–3.746 | 0.1460 | |||
| Clinical T staging: T3 + T4 vs. T1 + T2 | 0.900 | 0.470–1.723 | 0.7510 | |||
| ER status: positive vs. negative | 0.396 | 0.225–0.698 | 0.0010 | 0.585 | 0.277–1.232 | 0.1580 |
| PR status: positive vs. negative | 0.348 | 0.187–0.645 | <0.0010 | 0.413 | 0.185–0.924 | 0.0310 |
| HER2 status and Herceptin usage | ||||||
| HER2 negative | Reference | Reference | ||||
| HER2 positive but not using Herceptin | 0.889 | 0.475–1.664 | 0.7130 | 0.698 | 0.367–1.331 | 0.2750 |
| HER2 positive and using Herceptin | 0.219 | 0.067–0.717 | 0.0120 | 0.240 | 0.072–0.797 | 0.0200 |
| Ki67 index (%): ≥30 vs. <30 | 1.193 | 0.508–2.802 | 0.6850 | |||
| Palpable of ISLN before NAC: yes vs. no | 1.594 | 0.887–2.862 | 0.1190 | |||
| NAC regimens | ||||||
| Anthracycline plus taxane | Reference | |||||
| Anthracycline based | 0.731 | 0.257–2.074 | 0.5550 | |||
| Taxane based | 0.893 | 0.427–1.868 | 0.7650 | |||
| NAC cycles: ≥5 vs. <5 | 0.788 | 0.434–1.431 | 0.4340 | |||
| RECIST-based treatment response: SD+PD vs. CR + PR | 1.366 | 0.612–3.047 | 0.4470 | |||
| size of ISLN after NAC (mm): ≥10 vs. <10 | 1.603 | 0.820–3.133 | 0.1680 | |||
| Breast surgery strategies: BCS + reconstruction vs. Mastectomy | 1.664 | 0.229–12.111 | 0.6150 | |||
| ISLND or not: yes vs. no | 0.974 | 0.386–2.457 | 0.9560 | |||
| Breast pCR: yes vs. no | 0.900 | 0.497–1.632 | 0.7290 | |||
| Axillary pCR: yes vs. no | 0.526 | 0.263–1.052 | 0.0690 | |||
| ALNR (%): <35 vs. ≥35 | 1.950 | 1.111–3.420 | 0.0200 | 2.030 | 1.139–3.617 | 0.0160 |
| Radiation dose: normal vs. high | 0.818 | 0.418–1.599 | 0.5560 | |||
ALNR: Axillary lymph node ratio; BCS: Breast-conserving surgery; CI: Confidence interval; CR: Complete response; ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; HR: hormone receptor; ISLN: Ipsilateral supraclavicular lymph node; ISLND: Ipsilateral supraclavicular lymph node dissection; NAC: Neoadjuvant chemotherapy; OS: Overall survival; pCR: Pathological complete response; PD: Progressive disease; PR: Progesterone receptor; RECIST: Response evaluation criteria in solid tumors; SD: Stable disease.